Nektar Therapeutics (NKTR): Price and Financial Metrics
Nektar Therapeutics (NKTR)
Today's Latest Price: $21.77 USD
0.36 (-1.63%)
Updated Jan 23 6:55pm
Add NKTR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
NKTR Stock Summary
- Of note is the ratio of Nektar Therapeutics's sales and general administrative expense to its total operating expenses; only 8.29% of US stocks have a lower such ratio.
- NKTR's price/sales ratio is 34.27; that's higher than the P/S ratio of 95.98% of US stocks.
- Revenue growth over the past 12 months for Nektar Therapeutics comes in at -90.35%, a number that bests just 0.86% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Nektar Therapeutics, a group of peers worth examining would be NVAX, ARDS, UMRX, ANAB, and UTHR.
- NKTR's SEC filings can be seen here. And to visit Nektar Therapeutics's official web site, go to www.nektar.com.
NKTR Daily Price Range
NKTR 52-Week Price Range
NKTR Stock Price Chart More Charts
NKTR Price/Volume Stats
| Current price | $21.77 | 52-week high | $47.11 |
| Prev. close | $22.13 | 52-week low | $15.64 |
| Day low | $21.36 | Volume | 1,593,700 |
| Day high | $22.20 | Avg. volume | 3,759,080 |
| 50-day MA | $21.45 | Dividend yield | N/A |
| 200-day MA | $25.22 | Market Cap | 3.83B |
Nektar Therapeutics (NKTR) Company Bio
Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
Top Stories View All
The Economy Keeps Weakening: 2 Critical Things Investors Need to Know
2 Tech Stocks To Consider Buying On Dips
Will Shares of Innovative Industrial Properties (IIPR) Continue Rising in 2020?
Best & Worst Performing Stock Industries for January 23, 2020
Best & Worst Performing Small Cap Stocks for January 23, 2020
View All Top Stories
Loading social stream, please wait...